--- title: "The 2026 Market Misfits: From EV Nightmares to Absurd AI Pivots" type: "News" locale: "en" url: "https://longbridge.com/en/news/293012953.md" description: "When you group these ten unrelated companies, you get a brutally honest snapshot of the 2026 market. From Avis swallowing a massive EV writedown to U Power’s baffling AI pivot, here is who is actually surviving." datetime: "2026-07-17T09:12:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293012953.md) - [en](https://longbridge.com/en/news/293012953.md) - [zh-HK](https://longbridge.com/zh-HK/news/293012953.md) --- # The 2026 Market Misfits: From EV Nightmares to Absurd AI Pivots This is stupid and here's why. Usually, the market tries to group companies by neat, coherent sector logic. But when you look at this chaotic bundle of misfits in 2026, the only unifying thread is survival. Some are faking pivots, some are bleeding cash, and a rare few are actually executing. Let’s cut through the noise and see what is really happening. Let's start with the bottom-feeders desperately avoiding delisting. Outlook Therapeutics (OTLK.US) finally managed to claw its way back into Nasdaq's compliance graces by late June 2026. They are trying to commercialize an ophthalmic formulation of bevacizumab, having generated a microscopic USD 1.4M in annual revenue against a USD 62.4M net loss for fiscal 2025. Good luck with that. Over in Tokyo, PicoCELA (PCLA.US) is also fighting the delisting reaper, shuffling its executive deck in July and approving a preferred stock capital increase. Changing your CTO won't magically fix your broken business model. Then we have the pivoters desperately clinging to the buzzwords of 2026. Take U Power (UCAR.US). They used to do EV battery swapping, and now they are suddenly providing "AI-driven energy management" for data centers, piloting a 3MW project in Thailand in May. This is absurd. Everyone wants a piece of the AI pie, but this transition is beyond jarring. Equally ridiculous is High Roller Technologies (ROLR.US). An online casino launching a crypto prediction market after getting an NFA license in June? When gambling houses rebrand as derivative platforms, you know the bubble is fully inflated. Meanwhile, Blaize Holdings (BZAI.US) is supposedly an AI hardware company but has been absolutely silent. You can't raise capital if you are asleep at the wheel. At least Ideal Power (IPWR.US) is doing actual work, filing for a USD 75M mixed shelf offering in July to fund its semiconductor commercialization. Even the larger caps are busy cleaning up their own messes. Avis Budget Group (CAR.US) took a massive USD 518M impairment hit recently. Why? Because the residual value of their EV fleet cratered. I told you buying a massive fleet of EVs was a terrible idea. Over in pharma, Sanofi (SNY.US) shook up its R&D leadership in June 2026, bringing in Paulo Fontoura to revive its pipeline. And Adidas (ADDYY.US)? They are just quietly existing in the background, looking completely out of place in this chaotic lineup. Finally, a lesson in actual resilience. TAL Education Group (TAL.US) survived existential regulatory crackdowns and just posted USD 3.01B in fiscal 2026 net revenue, up 33.7% year-over-year. They even managed a net income of USD 530.8M. Why aren't the rest of you moving faster to fix your core businesses instead of chasing the next shiny object? _This article does not constitute investment advice._ ### Related Stocks - [IPWR.US](https://longbridge.com/en/quote/IPWR.US.md) - [PCLA.US](https://longbridge.com/en/quote/PCLA.US.md) - [OTLK.US](https://longbridge.com/en/quote/OTLK.US.md) - [SNY.US](https://longbridge.com/en/quote/SNY.US.md) - [BZAI.US](https://longbridge.com/en/quote/BZAI.US.md) - [UCAR.US](https://longbridge.com/en/quote/UCAR.US.md) - [CAR.US](https://longbridge.com/en/quote/CAR.US.md) - [ROLR.US](https://longbridge.com/en/quote/ROLR.US.md) - [ADDYY.US](https://longbridge.com/en/quote/ADDYY.US.md) - [TAL.US](https://longbridge.com/en/quote/TAL.US.md) ## Related News & Research - [Adidas to open concept store in Mall of America](https://longbridge.com/en/news/293953192.md) - [Is Sanofi (ENXTPA:SAN) Still Undervalued After Its Eczema Drug Setback?](https://longbridge.com/en/news/293813235.md) - [Sanofi halts atopic dermatitis development of amlitelimab, drops global filing plans](https://longbridge.com/en/news/293705733.md) - [Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering | SCTX Stock News](https://longbridge.com/en/news/293684218.md) - [Sanofi Drops Dupixent Successor Candidate After Assessing Data](https://longbridge.com/en/news/293787328.md)